Table 2.
Demographic characteristics and treatment outcomes of patients with fungaemia (N = 110)
|
Characteristics |
Type of fungaemia,N(%) |
Pvalue |
||
|---|---|---|---|---|
| Non-Candidafungaemia | Candidaemia | Overall | ||
| |
11 (10.0) |
99 (90.0) |
110 (100) |
|
| Age, years a |
66 (60–71) |
65 (49–74) |
65 (54–73) |
0.80 |
| Female gender |
5 (45.5) |
54 (54.5) |
59 (53.6) |
0.57 |
| Hospital-acquired infection |
11 (100) |
95 (96.0) |
106 (96.4) |
0.65 |
| Days of prior hospitalisation a, b |
47 (11–66) |
30 (12–60) |
30 (12–60) |
0.62 |
| Admission ward at fungaemia onset |
0.71 |
|||
| Surgical ward |
3 (27.3) |
40 (40.4) |
43 (39.1) |
|
| Medical ward |
6 (54.5) |
41 (41.4) |
47 (42.7) |
|
| ICU |
2 (18.2) |
14 (14.1) |
16 (14.5) |
|
| Co-morbidities |
11 (100) |
92 (92.9) |
103 (93.6) |
0.47 |
| Solid malignancy |
0 (0) |
45 (45.5) |
45 (40.9) |
< 0.01* |
| Diabetes mellitus |
5 (45.5) |
25 (25.3) |
30 (27.3) |
0.14 |
| Gastrointestinal/hepatobiliary disease |
6 (54.5) |
60 (60.6) |
66 (60.0) |
0.47 |
| Chronic kidney disease |
6 (54.5) |
18 (18.2) |
24 (21.8) |
0.01* |
| Haematologic malignancy |
1 (9.1) |
14 (14.1) |
15 (13.6) |
0.54 |
| Cardiovascular disease |
3 (27.3) |
17 (17.2) |
20 (18.2) |
0.32 |
| Collagen disease |
3 (27.3) |
9 (9.1) |
12 (10.9) |
0.09* |
| Underlying conditions | ||||
| Prior ICU admission |
5 (45.5) |
31 (31.3) |
36 (32.7) |
0.27 |
| Neutropaenia |
1 (9.1) |
7 (7.1) |
8 (7.3) |
0.58 |
| Prior bacteraemia |
7 (63.6) |
32 (32.3) |
39 (35.5) |
0.04* |
| Colonisation by causative yeasts |
8 (72.7) |
41 (41.4) |
49 (44.5) |
0.05* |
| Polymicrobial bacteraemia |
5 (45.5) |
23 (23.2) |
28 (25.5) |
0.11 |
| Assisted ventilation |
2 (18.2) |
17 (17.2) |
19 (17.3) |
0.60 |
| Renal replacement therapy |
5 (45.5) |
9 (9.1) |
14 (12.7) |
< 0.01* |
| Indwelling Foley catheter |
7 (63.6) |
42 (42.4) |
49 (44.5) |
0.15 |
| Central venous catheterisation |
8 (72.7) |
82 (82.8) |
90 (8.18) |
0.32 |
| Parenteral nutrition |
8 (72.7) |
80 (80.8) |
88 (80.0) |
0.38 |
| Enteral nutrition |
9 (81.8) |
56 (56.6) |
65 (59.1) |
0.09* |
| Corticosteroid therapy |
7 (63.6) |
31 (31.3) |
38 (34.5) |
0.04* |
| Chemotherapy |
0 (0) |
27 (27.3) |
27 (24.5) |
0.04* |
| Other immunosuppressant therapy |
3 (27.3) |
8 (8.1) |
11 (10.0) |
0.08* |
| Prior antibiotic therapy |
10 (90.9) |
89 (89.9) |
99 (90.0) |
0.70 |
| Prior antifungal therapy |
4 (36.4) |
18 (18.2) |
22 (20.0) |
0.15 |
| Prior surgical procedures |
2 (18.2) |
28 (28.3) |
30 (27.3) |
0.38 |
| Abdominal surgery |
1 (9.1) |
19 (19.2) |
20 (18.2) |
0.37 |
| Other surgery |
1 (9.1) |
10 (10.1) |
11 (10.0) |
0.70 |
| SOFA score a |
11 (3–17) |
3 (1–9) |
3.5 (1.8-10) |
0.02* |
| Death within 30 days | 6 (54.5) | 21 (21.2) | 27 (24.5) | 0.03* |
ICU: intensive care unit; SOFA: sequential organ failure assessment.
Data are presented as median values (interquartile range) for continuous variables and numbers of cases (%) for categorical variables.
P values are marked in bold if <0.05.
a Variables categorised as an ordinal scale in 1-point increments: OR > 1 is the increase in likelihood of the outcome with a 1-point increase in the factor.
b Days of hospitalisation prior to fungaemia onset.
* P < 0.10, variable was included in the multivariate analysis of outcomes from non-Candida fungaemia versus candidaemia.